Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.110 | 0.500 | 0.390 |
Shares | 99.890 | 99.890 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 18.510 | 15.297 |
Price to Book | 3.461 | 2.578 |
Price to Sales | 2.520 | 1.726 |
Price to Cash Flow | 12.041 | 9.699 |
Dividend Yield | 3.103 | 3.496 |
5 Years Earnings Growth | 10.467 | 8.780 |
Name | Net % | Category Average |
---|---|---|
Technology | 24.090 | 14.754 |
Industrials | 18.670 | 12.505 |
Financial Services | 18.460 | 18.402 |
Healthcare | 11.010 | 14.157 |
Consumer Cyclical | 10.700 | 8.499 |
Utilities | 6.640 | 5.458 |
Real Estate | 3.800 | 3.858 |
Consumer Defensive | 3.020 | 11.734 |
Communication Services | 2.600 | 6.714 |
Basic Materials | 1.020 | 3.784 |
Number of long holdings: 46
Number of short holdings: 17
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Edenred | FR0010908533 | 4.74 | 46.80 | -1.06% | |
Microsoft | US5949181045 | 4.74 | 420.21 | -0.19% | |
Broadcom | US11135F1012 | 4.43 | 1,395.29 | -1.19% | |
Merck&Co | US58933Y1055 | 4.31 | 131.20 | +0.24% | |
Terna | IT0003242622 | 3.93 | 7.858 | -1.01% | |
Novo Nordisk A/S Class B | DK0060534915 | 3.80 | - | - | |
Steadfast Group | AU000000SDF8 | 3.79 | 5.69 | -2.40% | |
Accenture | IE00B4BNMY34 | 3.73 | 303.62 | -1.42% | |
Taiwan Semiconductor | US8740391003 | 3.49 | 151.68 | -0.36% | |
Watsco | US9426222009 | 3.46 | 477.50 | +1.48% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Mirabaud Eq Glbl Focus A CHF Acc | 235.23M | -2.52 | -6.25 | - | ||
Mirabaud Glbl Eq HiIncome A CHF Acc | 71.61M | -0.23 | 2.51 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review